Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as ReyatazA , and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of ... (more)
http://ift.tt/1iO1ofs
http://ift.tt/1iO1ofs
No comments:
Post a Comment